Status:
COMPLETED
Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome
Lead Sponsor:
Samsung Medical Center
Conditions:
Myofascial Pain Syndrome
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
Myofascial pain syndrome (MPS) is the most common cause of persistent regional pain characterized by myofascial trigger points. Trigger point injection (TPI) using local anesthetics is one of the most...
Detailed Description
Study approval was obtained from Institutional Review Board (IRB) of Samsung medical center, and written informed consent was obtained from all participants. The required sample size was determined b...
Eligibility Criteria
Inclusion
- Adults
- Aged 25-75 years
- Diagnosed with myofascial pain syndrome affecting both trapezius muscles
Exclusion
- History of allergy to lidocaine or hyaluronidase
- Anticoagulant medication or antiplatelet agent within 5 days before the study
- Analgesic medication, including non-steroidal anti-inflammatory drugs, tramadol, acetaminophen, or opioids within 5 days of the study
- Pain related to trauma within 6 months before the study
- History of cervical or shoulder surgery
- TPI within 3 months in the same region
- Fibromyalgia
- Cervical radiculopathy or myelopathy
- Obesity, defined as body mass index of 27.5 or higher
- Other medical or psychological conditions (cancer, rheumatoid arthritis, endocrine disease, major depression, schizophrenia)
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT02293083
Start Date
April 1 2010
End Date
May 1 2011
Last Update
November 18 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.